A detailed history of Parallel Advisors, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 40 shares of ALT stock, worth $322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40
Previous 40 -0.0%
Holding current value
$322
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$10.67 - $22.41 $4,268 - $8,964
-400 Reduced 90.91%
40 $1,000
Q2 2022

Aug 01, 2022

BUY
$3.94 - $11.77 $1,520 - $4,543
386 Added 714.81%
440 $5,000
Q1 2022

Apr 28, 2022

SELL
$5.9 - $9.45 $2,188 - $3,505
-371 Reduced 87.29%
54 $0
Q4 2021

Jan 20, 2022

SELL
$8.69 - $12.48 $2,685 - $3,856
-309 Reduced 42.1%
425 $4,000
Q1 2021

Apr 23, 2021

BUY
$12.71 - $24.31 $9,329 - $17,843
734 New
734 $10,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.